Erschienen in:
26.08.2020 | BRIEF COMMUNICATION
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
verfasst von:
Fabrizio Vernieri, Claudia Altamura, Cinzia Aurilia, Nicoletta Brunelli, Gabriella Egeo, Luisa Fofi, Carmelina Maria Costa, Adriana Fallacara, Valentina Favoni, Giulia Pierangeli, Marco Aguggia, Davide Bertuzzo, Maria Albanese, Paola Di Fiore, Fabio Frediani, Sabina Cevoli, Piero Barbanti
Erschienen in:
Neurological Sciences
|
Sonderheft 2/2020
Einloggen, um Zugang zu erhalten
Excerpt
The development of drugs targeting the trigeminal sensory calcitonin gene-related peptide (CGRP) or its receptor is actually opening a new era for the treatment of migraine. Quite a number of randomized controlled trials demonstrated that the anti-CGRP receptor, erenumab, and the anti-CGRP antibodies, galcanezumab, fremanezumab, and eptinezumab, are effective and safe in patients with migraine. Recently, real-life studies with erenumab have also confirmed trial data in a real-world setting. …